SURGE Therapeutics, Inc. — Form D
SURGE Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2023-06-02. The offering totals $50.0M, of which $32.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-06-02
- Form: D
- Accession: 0001834664-23-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.0M
- Amount sold: $32.0M
- Remaining: $18.0M
- Investors: 22
- Date of first sale: 2023-05-19
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-483195
Issuer
- Name: SURGE Therapeutics, Inc.
- CIK: 0001834664
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, 02142
- Phone: 617-909-8181
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Jason S Coloma | Director | Cambridge, MA |
| Ali S Farahanchi | Director | Cambridge, MA |
| Gary S Goldberg | Director | Cambridge, MA |
| Michael S Goldberg | Director | Cambridge, MA |
| Kouki S Harasaki | Director | Menlo Park, CA |
| Chuck S Carignan | Executive Officer | Cambridge, MA |
| Michael S Goldberg | Executive Officer | Cambridge, MA |
| Antonio S Gualberto | Executive Officer | Cambridge, MA |
| Michael Goldberg | Director | Weston, CT |
| Michael Goldberg | Executive Officer | Weston, CT |
| Gary Goldberg | Director | Mullica Hill, NJ |
| Gary Goldberg | Executive Officer | Mullica Hill, NJ |
Other filings by this issuer (1)
More